Actively Recruiting
In-human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-02-05
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the uptake of the imaging agent [68Ga]-pentixafor using PET/CT scans in people with certain blood cancers, including monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), non-Hodgkin lymphoma (NHL), and histiocytic neoplasms such as Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), and Rosai-Dorfman disease (RDD). The study focuses on how this imaging agent behaves in these conditions to better understand tumor activity. All participants will receive an intravenous injection of 3 to 5 mCi of [68Ga]-pentixafor followed by imaging on a hybrid PET/CT scanner. The PET/CT scan includes a low-dose CT for image correction and lasts approximately 1.5 hours. Some participants may have two scans. Various factors, such as tolerance to the scan or availability of the imaging agent or scanner, may affect whether imaging can be performed. Participants will be monitored for the uptake and pharmacokinetics of [68Ga]-pentixafor using PET/CT imaging. Tumor uptake will be measured as the standard uptake value (SUV) over one year. The study includes assessments like pregnancy testing for women of childbearing potential. The total duration and specific follow-up details beyond imaging and uptake measurement are not specified.
CONDITIONS
Brief Title
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Histologically confirmed treatment-na�efve, therapy-refractory, or relapsed blood cancers
- Diagnosis of indolent B- or T-cell Non-Hodgkin lymphoma with measurable disease
- Diagnosis of histiocytic neoplasms including Langerhans cell histiocytosis, Erdheim-Chester disease, or Rosai-Dorfman disease
- Diagnosis of monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or multiple myeloma (MM) as defined by IMWG
- Diagnosis of solid tumors such as lung cancers, meningioma, or adrenocortical neoplasms
- Negative serum pregnancy test for females of childbearing potential within 2 weeks before enrollment or negative urine pregnancy test on intervention day
- Patients treated or evaluated at Memorial Sloan Kettering Cancer Center (MSKCC)
You will not qualify if you...
- Currently breastfeeding
- History of renal functional disorders with severe impairment (eGFR less than 30)
- Refusal or inability to tolerate the PET/CT scanning procedure (e.g., due to claustrophobia)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive an intravenous injection of [68Ga]-Pentixafor and undergo PET/CT imaging to evaluate tumor uptake and pharmacokinetics.
1 imaging visit lasting approximately 1.5 hours; some participants may have 2 scans
Duration - Up to 1 year
Participants are followed to assess tumor uptake values over time as part of long-term diagnostic evaluation.
Follow-up visits as scheduled for outcome assessments
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
A
Anton Nosov, MD
H
Heiko Schoder, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here